Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

The rhomboid-like pseudoprotease TMEM115 defines a two-factor mechanism for Rab6A effector recruitment

Created on 09 Sep 2026

Authors

Zhang, B., Bryant, O., Muschalik, N., Levet, C., Charlier, L., Moncada Pazos, A., Jajcanin Jozic, N., Shen, X., Lu, F., Gowda, A., Duesterhoeft, S., Lea, S. M., Munro, S., Freeman, M.

Abstract

Protein trafficking and organelle identity depends on precise localisation of membrane proteins, anchored by small GTPases that bind to specific cellular compartments. Here we show that the rhomboid-like pseudoprotease TMEM115 defines an unexpected two-factor system with Rab6A to target the golgin TMF1. In the absence of TMEM115, TMF1 is delocalised from the rim of the Golgi apparatus; instead, it is retained in Golgi-targeting vesicles. TMEM115, TMF1, and Rab6A assemble into a ternary complex which, in striking contrast to canonical rhomboid-like mechanisms, is independent of transmembrane domain interactions. Disruption of the TMEM115-Rab6A-TMF1 complex affects the efficiency of trafficking of proteins from the Golgi; moreover, human disease-associated mutations target the interfaces of this ternary complex, thereby delocalising TMF1 from the Golgi. Finally, loss of TMEM115 in Drosophila causes abnormal Golgi morphology, and mouse knockouts undergo perinatal death. We propose that two-factor effector recruitment defines a mechanism for precise Rab GTPase-mediated membrane targeting.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 09 Sep 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 17
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement